PMID- 22354323
OWN - NLM
STAT- MEDLINE
DCOM- 20120807
LR  - 20171116
IS  - 1423-0275 (Electronic)
IS  - 0301-1569 (Linking)
VI  - 74
IP  - 2
DP  - 2012
TI  - CD24: a novel cancer biomarker in laryngeal squamous cell carcinoma.
PG  - 78-85
LID - 10.1159/000335584 [doi]
AB  - PURPOSE: To investigate the role of CD24 in tumor invasion and the clinical 
      significance of its expression in laryngeal squamous cell carcinoma (LSCC). 
      PROCEDURES: CD24 expression was measured in Hep-2 cell lines and tumor and 
      peritumoral tissues by quantitative real-time PCR and Western blot analysis. The 
      role of CD24 in LSCC was investigated by CD24 depletion using small interfering 
      RNA. Tumor tissue microarrays with samples from 102 LSCC patients were used to 
      detect expression of CD24 and proliferating cell nuclear antigen (PCNA). 
      Prognostic significance was assessed using Kaplan-Meier survival estimates and 
      log-rank tests. RESULTS: CD24 was overexpressed in the LSCC cell line and in 
      tumor tissues. Depletion of CD24 caused a notable decrease in cell proliferation, 
      migration and invasiveness in vitro. High CD24 expression was significantly 
      associated with T clinic stage, lymph node metastasis and tumor size (p < 0.05). 
      Patients suffering from LSCC recurrence had higher levels of CD24 protein than 
      those without recurrence (p < 0.0001). The proportion of patients with high PCNA 
      expression was significantly greater among patients with CD24+ LSCC than those 
      with CD24- LSCC (p = 0.000). Univariate and multivariate analyses revealed that 
      CD24 was a significant predictor for overall survival. CONCLUSIONS: 
      Overexpression of CD24 in LSCC is associated with invasiveness, metastatic 
      potential and high tumor proliferation status. CD24 may be a promising strategy 
      for the future treatment of LSCC metastasis and recurrence.
CI  - Copyright (c) 2012 S. Karger AG, Basel.
FAU - Shi, Yong
AU  - Shi Y
AD  - Department of Otolaryngology, Head and Neck Surgery, Fudan University Eye, Ear, 
      Nose and Throat Hospital, Shanghai, China.
FAU - Gong, Hong-Li
AU  - Gong HL
FAU - Zhou, Liang
AU  - Zhou L
FAU - Tian, Jie
AU  - Tian J
FAU - Wang, Yang
AU  - Wang Y
LA  - eng
PT  - Journal Article
DEP - 20120221
PL  - Switzerland
TA  - ORL J Otorhinolaryngol Relat Spec
JT  - ORL; journal for oto-rhino-laryngology and its related specialties
JID - 0334721
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CD24 Antigen)
RN  - 0 (CD24 protein, human)
RN  - 0 (Proliferating Cell Nuclear Antigen)
RN  - 0 (RNA, Small Interfering)
SB  - IM
MH  - Biomarkers, Tumor/*genetics/metabolism
MH  - CD24 Antigen/*genetics/metabolism
MH  - Carcinoma, Squamous Cell/*genetics/mortality/secondary
MH  - Cell Division/physiology
MH  - Female
MH  - Gene Expression Regulation, Neoplastic
MH  - HEK293 Cells
MH  - Hep G2 Cells
MH  - Humans
MH  - Laryngeal Neoplasms/*genetics/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Invasiveness
MH  - Neoplasm Recurrence, Local/genetics/mortality
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Proliferating Cell Nuclear Antigen/genetics/metabolism
MH  - RNA, Small Interfering/genetics
MH  - Risk Factors
MH  - Survival Analysis
EDAT- 2012/02/23 06:00
MHDA- 2012/08/08 06:00
CRDT- 2012/02/23 06:00
PHST- 2011/07/01 00:00 [received]
PHST- 2011/11/28 00:00 [accepted]
PHST- 2012/02/23 06:00 [entrez]
PHST- 2012/02/23 06:00 [pubmed]
PHST- 2012/08/08 06:00 [medline]
AID - 000335584 [pii]
AID - 10.1159/000335584 [doi]
PST - ppublish
SO  - ORL J Otorhinolaryngol Relat Spec. 2012;74(2):78-85. doi: 10.1159/000335584. Epub 
      2012 Feb 21.